Polymorphism Clinical Trial
— CYP19Official title:
Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea
Verified date | April 2014 |
Source | Samsung Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | South Korea: Institutiona Review Board |
Study type | Observational |
Aromatase(CYP19)inhibitor is one of the major antihormonal drug for breast cancer in postmenopausal women. The variation of CYP19 may affect the effect of aromatase inhibitor. However, the incidence of variation of CYP19 in Korea has not known. Therefore, the investigators want to know the incidence of variation of CYP19 and to assess the effect of these variations of CYP19 to aromatase inhibitor users.
Status | Suspended |
Enrollment | 300 |
Est. completion date | December 2015 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | N/A to 80 Years |
Eligibility |
Inclusion Criteria: - hormone receptor positiveBreast cancer patient - postmenopausal women - first user of aromatase inhibitor Exclusion Criteria: - premenopausal - The patient who take the other antihormonal therapy - osteoporosis patients |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Samsung Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The prevalence of CYP19 polymorphism | 12. 31. 2011 | No | |
Secondary | The effect of CYP19 polymorphism to the prognosis of AI user | 12. 31. 2016 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03859882 -
Protocol PERCAF 2018
|
N/A | |
Recruiting |
NCT03114826 -
Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients
|
N/A | |
Completed |
NCT02743468 -
Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function
|
||
Completed |
NCT01708083 -
Polymorphids an mRNA Expression in Obese Genes
|
N/A | |
Completed |
NCT01239914 -
CathOlic Medical Center percutAneous Coronary inTervention Registry (COACT)
|
||
Completed |
NCT03855774 -
Polymorphisms, Caffeine and Sleep Disorders
|
N/A | |
Recruiting |
NCT04565834 -
Effect of Genetic Alterations in Key Genes in the Kynurenine Pathway on Suicidal Behavior
|
||
Not yet recruiting |
NCT03262363 -
Curcumin on NFE2L2 Gene Expression, Antioxidant Capacity and Renal Function According to rs35652124 in Diabetic Nephropathy
|
Phase 2/Phase 3 |